Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
Y-mAbs Therapeutics, Inc. (YMAB)
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel radioimmunotherapy and antibody-based therapeutic products for the treatment of cancer, today announced the appointment of Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit. “I am pleased to welcome Doug to Y-mAbs as the new DANYELZA Business Unit head,” said Michael Rossi, President and Chief Executive Officer. “We believe Doug’s extensive experience leading pharmaceutical commercialization and operations on a global scale will be instrumental in our continued commercial
Read more
Impact Snapshot
Event Time:
YMAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
YMAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
YMAB alerts
High impacting Y-mAbs Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
YMAB
News
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Truist Financial Co. from $21.00 to $18.00. They now have a "buy" rating on the stock.MarketBeat
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Bank of America Co. from $14.00 to $12.00. They now have a "neutral" rating on the stock.MarketBeat
- Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) had its price target lowered by analysts at Morgan Stanley from $11.00 to $7.00. They now have an "underweight" rating on the stock.MarketBeat
- Y-mAbs Therapeutics (NASDAQ:YMAB) shareholders have endured a 79% loss from investing in the stock five years ago [Yahoo! Finance]Yahoo! Finance
- Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate DevelopmentsGlobeNewswire
YMAB
Earnings
- 3/4/25 - Miss
YMAB
Sec Filings
- 3/11/25 - Form 4
- 3/11/25 - Form 4
- 3/7/25 - Form 144
- YMAB's page on the SEC website